Oral epetraborole program in polycythemia vera advancing toward Phase 2 Phase 2 investigator-initiated trial with epetraborole for M. abscessus lung

MENLO PARK, Calif. --(BUSINESS WIRE)--May 7, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics

MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 31, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule

Phase 2 study of oral epetraborole in polycythemia vera (PV) expected to begin 3Q26 with potential for data readouts as

MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 9, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule

Substantial clinical evidence provides rationale to initiate Phase 2 study in PV Phase 2 study expected to begin 3Q26 with

MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 17, 2026-- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company advancing novel small molecule therapeutics

Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026

Designation recognizes ISP-002, an engineered B cell therapy designed for sustained enzyme delivery SAN FRANCISCO, Jan. 26, 2026 /PRNewswire/ — Immusoft